An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Clinical trial NCT02610777 · COMPLETED
Trial details
- NCT number
- NCT02610777
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-14
- Primary completion
- 2019-09-04
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.